Azitra, Inc. to Present at The Microcap Conference

Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [2] - The company's lead product, ATR-12, is designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options [2] - ATR-12 is currently being evaluated in a Phase 1b clinical trial in adult patients with Netherton syndrome [2] - Azitra's second product, ATR-04, targets EGFR inhibitor associated rash and has received Fast Track designation from the FDA [2] - Approximately 150,000 people in the U.S. are affected by EGFRi associated rash [2] - Azitra utilizes a proprietary platform of engineered proteins and a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning technology [2] Upcoming Events - Azitra will present at The Microcap Conference 2025 on January 29, 2025, at 11:00 a.m. ET [1] - The event will take place at Borgata Hotel Casino & Spa, Atlantic City, NJ [1] - CEO Francisco Salva will lead the presentation, and the management team will hold one-on-one meetings with registered investors and potential partners [1]